Birth Defects Res by Kapoor, Renuka et al.
Prevalence and descriptive epidemiology of infantile 
hypertrophic pyloric stenosis in the United States: A multistate, 
population-based retrospective study, 1999–2010
Renuka Kapoor1, Vijaya Kancherla1, Yanyan Cao2, Jacob Oleson3, Jonathan Suhl2, Mark A 
Canfield4, Charlotte M Druschel5, Russell S Kirby6, Robert E Meyer7,8, Paul A Romitti2,3
1Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia
2Department of Epidemiology, College of Public Health, The University of Iowa, Iowa City, Iowa
3Department of Biostatistics, College of Public Health, The University of Iowa, Iowa City, Iowa
4Birth Defects Epidemiology and Surveillance Branch, Texas Department of State Health 
Services, Austin, Texas
5Department of Epidemiology and Biostatistics, University of Albany School of Public Health, 
State University of New York, New York, New York
6Department of Community and Family Health, College of Public Health, University of South 
Florida, Florida
7Birth Defects Monitoring Program, Division of Public Health, North Carolina Department of 
Health and Human Services, Raleigh, North Carolina
8Department of Maternal and Child Health, Gillings School of Global Public Health, University of 
North Carolina at Chapel Hill, Chapel Hill, North Carolina
Abstract
Background: Antecedents for infantile hypertrophic pyloric stenosis (IHPS) vary across studies; 
therefore, we conducted a multistate, population-based retrospective study of the prevalence and 
descriptive epidemiology of IHPS in the United States (US).
Methods: Data for IHPS cases (n = 29,554) delivered from 1999–2010 and enumerated from 11 
US population-based birth defect surveillance programs, along with data for live births (n = 
14,707,418) delivered within the same birth period and jurisdictions, were analyzed using Poisson 
regression to estimate IHPS prevalence per 10,000 live births. Additional data on deliveries from 
1999–2005 from seven of these programs were analyzed using multivariable logistic regression to 
estimate adjusted prevalence ratios (aPR)s and 95% confidence intervals (CI)s for selected infant 
and parental characteristics.
Results: Overall, IHPS prevalence from 1999–2010 was 20.09 (95% CI = 19.87, 20.32) per 
10,000 live births, with statistically significant increases from 2003–2006 and decreases from 
2007–2010. Compared to their respective referents, aPRs were higher in magnitude for males, 
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preterm births, and multiple births, but lower for birth weights <2,500 g. The aPRs for all cases 
increased with decreasing parental age, maternal education, and maternal parity, but decreased for 
parental race/ethnicity other than non-Hispanic White. Estimates restricted to isolated cases or 
stratified by infant sex were similar to those for all cases.
Conclusions: This study covers one of the largest samples and longest temporal period 
examined for IHPS in the US. Similar to findings reported in Europe, estimates suggest that IHPS 
prevalence has decreased recently in the US. Additional analyses supported associations with 
several infant and parental characteristics.
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1 | INTRODUCTION
Infantile hypertrophic pyloric stenosis (IHPS) is characterized by muscular hypertrophy of 
the pyloric sphincter, causing obstruction of the gastric outlet and projectile vomiting in the 
newborn. This defect usually presents at 2–12 weeks after birth, often in a previously 
healthy infant, with peak onset at week 5 (Jobson & Hall, 2016). IHPS is one of the most 
frequently treated surgical conditions in children (El-Gohary, Abdelhafeez, Paton, Gosain, & 
Murphy, 2018). If left untreated, IHPS can lead to dehydration, weight loss, metabolic 
alkalosis and, in severe cases, death (Spicer, 1982). Pyloromyotomy is the standard method 
of treatment for IHPS and generally has a good prognosis and low fatality rate (<1%) 
(reviewed in MacMahon, 2006; Tigges and Bigham, 2012).
A previous review has suggested an increased predisposition for IHPS in populations living 
in temperate regions of North America and Western Europe compared to those in tropical 
countries (Spicer, 1982). Reported prevalence estimates (per 10,000 live births) for IHPS 
range from 17 to 50 in the United States (US) (Applegate & Druschel, 1995; Markel, 
Proctor, Ying, & Winchester, 2015; Schechter, Torfs, & Bateson, 1997; St Louis et al., 2017) 
and Western Europe (de Laffolie, Turial, Heckmann, Zimmer, & Schier, 2012; Hedback, 
Abrahamsson, Husberg, Granholm, & Oden, 2001; O’Donoghue et al., 1993; Pedersen et al., 
2008; Sommerfield et al., 2008; Sule, Stone, & Gilmour, 2001). Some populations in 
Western Europe have reported declines in IHPS prevalence across different birth periods 
from the 1980s through the 2000s, although others have not (de Laffolie et al., 2012; 
O’Donoghue et al., 1993; Pedersen et al., 2008; Sommerfield et al., 2008). A US study 
reported a decline in prevalence in New York State from 1983–1990 (Applegate & Druschel, 
1995) and a more recent study using data from several US population-based birth defect 
surveillance programs showed rather stable prevalence from 1999–2007 (St Louis et al., 
2017).
The recurrence of IHPS in families suggests a genetic component for this defect (reviewed 
in MacMahon, 2006), and analyses of infant and parental characteristics suggest a role for 
non-inherited factors. Specifically, studies of infant characteristics report a fourfold or higher 
male excess of IHPS (Applegate & Druschel, 1995; Hedback et al., 2001; Krogh et al., 2012; 
Lammer & Edmonds, 1987; Markel et al., 2015; Schechter et al., 1997; To, Wajja, Wales, & 
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Langer, 2005; Vermes, Laszlo, Czeizel, & Acs, 2016; Wang, Waller, Hwang, Taylor, & 
Canfield, 2008) and largely positive associations with preterm birth (Krogh et al., 2012; 
Schechter et al., 1997; Stark, Rogers, Eberly, & Nylund, 2015; Svenningsson, Svensson, 
Akre, & Nordenskjold, 2014; Wang et al., 2008), but inconclusive findings for birth weight 
(Applegate & Druschel, 1995; Lammer & Edmonds, 1987; Schechter et al., 1997; Wang et 
al., 2008), multiple births (Applegate & Druschel, 1995; Markel et al., 2015; Rider, 
Stevenson, Rinsky, & Feldkamp, 2013; Schechter et al., 1997; Stark et al., 2015), and month 
or season of birth (Dodge, 1975; Kwok & Avery, 1967; Lammer & Edmonds, 1987; 
Schechter et al., 1997; Zamakhshary et al., 2011).
Studies of parental characteristics report varying associations with maternal (Applegate & 
Druschel, 1995; Krogh et al., 2012; Markel et al., 2015; Pedersen et al., 2008; Schechter et 
al., 1997; Svenningsson et al., 2014; Wang et al., 2008) and paternal (Archer, Langlois, 
Suarez, Brender, & Shanmugam, 2007; Grewal, Carmichael, Yang, & Shaw, 2012; 
McIntosh, Olshan, & Baird, 1995) age at delivery. Similarly, varying associations have been 
reported with maternal race/ethnicity with the highest risks observed among non-Hispanic 
White mothers and lower risks for non-Hispanic Blacks, Hispanics (Applegate & Druschel, 
1995; Lammer & Edmonds, 1987; Markel et al., 2015; Schechter et al., 1997; Wang et al., 
2008), and Asians (Markel et al., 2015; Schechter et al., 1997; Wang et al., 2008). 
Conversely, more consistent associations have been reported for maternal education at 
delivery with decreasing prevalence observed with increasing education (Applegate & 
Druschel, 1995; Markel et al., 2015; To et al., 2005; Wang et al., 2008) and for maternal 
parity with decreasing prevalence observed with increasing parity (Applegate & Druschel, 
1995; Dodge, 1975; Krogh et al., 2012; Schechter et al., 1997; Svenningsson et al., 2014; 
Wang et al., 2008). Few previous studies of infant or parental characteristics examined 
associations stratified by IHPS phenotype (isolated vs. multiple birth defects) or by infant 
sex.
The differing temporal reports of IHPS prevalence and somewhat inconsistent findings from 
previous descriptive studies on infant and parental characteristics suggest the need for a 
large study among a racially/ethnically diverse population by pooling population-based data 
on cases enumerated using systematic surveillance methods and comparing to population-
based data on live births. To accomplish this, we used retrospective data from 11 US 
population-based birth defect surveillance programs to conduct a comprehensive 
investigation of the prevalence and descriptive epidemiology of IHPS. Our findings offer an 
improved understanding of the prevalence and descriptive characteristics of this defect in a 
large, well-described US population.
2 | METHODS
2.1 | Case enumeration and classification
Data on IHPS diagnosis among live births delivered from 1999–2010 were obtained from 11 
population-based birth defects surveillance programs, representing around 35% of the 
deliveries in the US. Of these 11 surveillance programs, eight used active case finding 
(Arkansas [AR], Arizona [AZ], Georgia [GA, Metropolitan Atlanta Surveillance Program 
operated by the Centers for Disease Control and Prevention], Hawaii [HI], Iowa [IA], North 
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Carolina [NC], Oklahoma [OK], and Texas [TX]), and three used passive case finding 
(Colorado [CO], Florida [FL], and New York State [NY]) to enumerate IHPS cases. All but 
three programs (birth period[s])–AZ (1999, 2000, 2003–2004), HI (1999–2005), and NC 
(2003–2010)--contributed data for each year of the 12-year birth period. IHPS cases were 
enumerated using either the International Classification of Diseases, 9th Edition, Clinical 
Modification (ICD-9-CM) diagnosis code 750.5 or the Centers for Disease Control and 
Prevention/British Pediatric Association code 750.51. These diagnosis codes also were used 
by each program to report IHPS cases for annual birth defect surveillance reports generated 
by the National Birth Defects Prevention Network (NBDPN). IHPS cases with out 
additional, unrelated birth defects of organ structure or function were classified as isolated 
cases with the remain der classified as multiple cases. To help ensure complete 
ascertainment of IHPS cases, each program contributing data to this report included live 
births followed to at least one-year of age.
2.2 | Birth data
Participating surveillance programs provided de-identified birth certificate data for the birth 
period(s) in which they enumerated IHPS cases. Birth certificate data were used to retrieve 
information on selected infant and parental characteristics for all live births.
2.3 | Infant and parental characteristics
For the birth period 1999–2005, de-identified birth certificate data for infant (sex, birth 
weight, clinical estimate of gestational age, season and year of birth, plurality), maternal 
(age at delivery, race/ethnicity, education at delivery, parity—calculated as the sum of 
number of previous live and nonlive births) and paternal (age at delivery, race/ethnicity) 
characteristics for IHPS cases and live births were obtained from participating surveillance 
programs. We were unable to examine gestational age and birth weight as continuous 
variables, because only categorical data were provided by the surveillance programs for each 
variable. Instead, we also created a combined gestational age (weeks) and birth weight 
(grams) variable with four categories: (a) term birth and normal birth weight (≥ 37 weeks 
and >2,500 g); (b) term birth and low birth weight (≥ 37 weeks and <2,500 g); (c) preterm 
and normal birth weight (<37 weeks and >2,500 g); and (d) preterm and low birth weight 
(<37 weeks and <2,500 g).
Overall, data were available for more than 99% of live births for each descriptive 
characteristic, except maternal race/ethnicity (80%), and parity (75%) and paternal race/
ethnicity (67%) (data not shown). For the birth period 2006–2010, only data for birth year 
and maternal race/ethnicity for IHPS cases and live births were available. These limited data 
were available for eight of the 11 surveillance programs via data submitted to the NBDPN 
for its annual surveillance report. Data through 2010 are the most recent IHPS data 
submitted to the NBDPN. Data for birth year and race/ethnicity for IHPS cases and live 
births delivered from 1999 to 2010 were used to estimate IHPS prevalence. The additional 
data available for IHPS cases and live births for 1999–2005 were used to examine the 
descriptive epidemiology of IHPS. The study protocol was reviewed and approved by the 
institutional review boards (IRBs) for each participating surveillance program, where 
required, as well as the IRBs at The University of Iowa and Emory University.
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2.4 | Prevalence analysis
We estimated IHPS prevalence (per 10,000 live births) as the ratio of the number of cases to 
the number of live births for the birth period 1999–2010 for each participating surveillance 
program. We also examined prevalence stratified by active and passive surveillance 
programs. Because three programs (AZ, HI, NC) were unable to provide data for all 12 
years, we declined to apply some analytic approaches, such as Joinpoint regression, across 
the individual program data. Instead, data were pooled across programs to estimate IHPS 
prevalence by birth year. A Poisson regression model with a log link function was used to 
estimate the prevalence for each individual surveillance program or birth year along with a 
95% confidence interval (CI) for the prevalence. A separate model was implemented for 
each surveillance program. In order to examine longitudinal trends in prevalence from 1999
—2010, a generalized linear mixed effects model assuming a Poisson distribution with a log 
link function was fitted for the number of IHPS cases diagnosed each birth year. Birth year, 
treated as a continuous linear variable, and state were considered fixed effects. A random 
intercept for state was included to account for clustering. Prevalence analyses were 
conducted using PROC GLIMMIX in SAS version (SAS Institute Inc., © 2013).
2.5 | Descriptive analysis
The descriptive epidemiology of IHPS was generated using data provided by each of the 11 
surveillance programs (Figure 1); data only were available for the years 1999–2005 to 
conduct descriptive analyses. Cases and live births were compared on the selected infant, 
maternal, and paternal characteristics listed in section 2.3 using the Pearson Chi square test. 
Analyses were conducted separately for all cases and isolated cases only. Crude and adjusted 
prevalence ratios ([cPR]s and [aPR]s, respectively) and their corresponding 95% CIs also 
were estimated to examine associations between IHPS and infant and parental characteristics 
using multivariable logistic regression analysis. Adjusted analyses were limited to data from 
seven states (AR, AZ, GA, IA, NC, OK, and TX) that provided data for all variables. 
Covariables included in the model were selected if a statistically significant bivariable 
association (p<.05) was observed between IHPS and the covariable or if the covariable was 
shown to be associated with IHPS in previous studies. Analyses for cPRs and aPRs were 
conducted separately for all cases and isolated cases, and those for aPRs were stratified by 
infant sex. Descriptive analyses were conducted using SAS version 9.4 (SAS Insititute Inc., 
2013).
3 | RESULTS
3.1 | Prevalence analysis
Our study included 14,707,418 live births and 29,554 IHPS cases from 11 US population-
based birth defect surveillance programs for all or selected years from 1999–2010. Of these 
11 surveillance programs, the lowest prevalence (per 10,000 live births) was observed in HI 
(5.52; 95% CI = 4.53, 7.00), and the highest prevalence was observed in OK (33.28; 95% CI 
= 31.88, 34.74) (Table 1). Combining available data across the 11 surveillance programs, the 
overall estimated prevalence for IHPS was 20.09 (95% CI = 19.87, 20.32). The combined 
prevalence estimate from the eight surveillance programs that contributed data for the entire 
12-year birth period remained stable from 1999–2002, but changed significantly (p<.05) 
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from 2003–2010, showing an increase from 2003–2006, followed by a decline from 2007–
2010. The combined prevalence by birth year was highest in 2006 at 25.06 and lowest in 
2010 at 17.29 (Figure 2). Further stratification of data by programs that conducted active 
(eight programs) or passive (three programs) surveillance yielded similar trends as observed 
when using data across all programs (data not shown).
3.2 | Descriptive analysis
Descriptive data for the 8,390,584 live births and 16,320 IHPS cases, including 13,922 
(85.3% of total) isolated cases, were available for the birth period 1999–2005 and pooled 
across 11 surveillance programs to analyze infant and parental characteristics (Table 2). 
Among all cases, the cPRs were higher for males, infants delivered at <37 weeks (preterm 
births), and infants from multiple gestations, but lower for those with birth weight <2,500 g; 
all estimates for season of birth were near unity. The cPRs also were higher for mothers or 
fathers <20 years of age at delivery than those 20–34 years of age, mothers with <12 years 
of education at delivery than those with 12 years of education, and for first-born children. 
Conversely, the cPRs for mothers or fathers ≥35 years of age or mothers >12 years of 
education at delivery were lower than their respective referents. Additionally, cPRs for 
mothers or fathers who were non-Hispanic Black, Hispanic, or other race/ethnicity (includes 
Asian/Pacific Islander, Native American, and other race/ethnicity) were lower than those 
who were non-Hispanic White. Findings for infant and parental characteristics for isolated 
cases tended to be similar to those for all cases.
The aPRs for several infant and parental characteristics tended to parallel their respective 
cPRs with an increase in magnitude persisting for male sex, plurality, first-born children, and 
mothers or fathers <20 years of age at delivery and a decrease in magnitude persisting for 
increasing maternal education and age at delivery, although the estimates for parity, maternal 
education and parental age at delivery were attenuated (Table 3). The direction of the 
associations for all low birth weight and all preterm gestational age did not differ from those 
for low birth weight among term gestational age infants and preterm gestational age among 
normal birth weight infants, respectively. The association for low birth weight among 
preterm gestational age infants was near unity (data not shown). A decrease in magnitude for 
aPRs persisted for birth weight <2,500 g and parental race/ethnicity other than non-Hispanic 
White, although the estimates for Hispanic parents were near unity. Findings for isolated 
cases tended to parallel those for all cases. Findings for aPRs stratified by sex were similar 
to findings from the main analysis (Figure 3).
4 | DISCUSSION
Our multistate, population-based retrospective study pooled data from 11 US birth defect 
surveillance programs to estimate the prevalence of IHPS from 1999–2010. Prevalence for 
all cases during this birth period was 20.09 per 10,000 live births and ranged from 5.52 in HI 
to 33.28 in OK. The difference in prevalence observed across surveillance programs may 
reflect the population demographics in these programs. As examples, the HI surveillance 
program monitors a higher proportion of Asian residents than the other programs included in 
our analyses, whereas the OK surveillance program monitors a high proportion of non-
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Hispanic Whites. IHPS prevalence estimates among offspring of Asian parents have been 
observed to be considerably lower than those among offspring of other parental races/
ethnicities (Schechter et al., 1997; Tiao, Tsai, Kuo, & Yang, 2011; Wang et al., 2008). In 
comparing estimates by birth year, we observed that prevalence was relatively stable through 
2002, followed by statistically significant increases from 2003–2006 and then significant 
decreases from 2007–2010. The cPRs estimated for our descriptive analysis using data from 
a subset of the birth period (1999–2005) and from surveillance programs with complete 
information on all selected characteristics suggested a higher prevalence of IHPS among 
males, preterm births, multiple births, and first-born children, as well as infants born to 
mothers or fathers <20 years of age at delivery or whose mothers had less than a high school 
education at delivery. These findings tended to persist in adjusted analyses, although 
estimates for parental age <20 years were attenuated. Findings restricted to isolated cases 
and those stratified by sex were similar to findings for all cases.
Our IHPS prevalence estimates differ from another US study which reported an overall 
prevalence (per 10,000 live births) of 15.8 (95% CI = 15.61, 16.04) from 1999–2007, but no 
significant change in prevalence during this birth period (St Louis et al., 2017). Although our 
study and that of St Louis et al. (2017) included mostly overlapping time frames and data 
from multiple surveillance programs in the US, only six programs (AZ, CO, FL, GA, NY, 
and TX) overlapped. Differences in the racial/ethnic distributions of cases and live births 
included between the two studies may have contributed to the variable findings for IHPS 
prevalence.
Our observation of a male predominance for IHPS was consistent with previous population-
based studies from the US (Applegate & Druschel, 1995; Lammer & Edmonds, 1987; 
Schechter et al., 1997) and European countries (Hedback et al., 2001; Krogh et al., 2012; 
Markel et al., 2015; Vermes et al., 2016). The inverse association we observed for birth 
weight <2,500 g was not directly comparable with previous studies because of differences in 
study methods. Conversely, the higher PRs we observed for preterm infants were consistent 
with previous studies that examined all IHPS cases (Krogh et al., 2012; Schechter et al., 
1997) and isolated IHPS cases (Schechter et al., 1997). Even so, the seemingly paradoxical 
findings we observed for low birth weight and preterm birth were observed when grouping 
birth weight and gestational age into meaningful categories considering small and large for 
gestational age. Additionally, our null findings for season of birth contrast with similar 
previous studies that reported seasonal variation in IHPS (Kwok & Avery, 1967; 
Zamakhshary et al., 2011), and our finding of increased prevalence among multiple births 
was consistent with two other recent studies (Rider et al., 2013; Stark et al., 2015). The 
results of a Texas study which used data that overlapped with those used in our study 
generally reported similar associations for infant sex and gestational age, although the Texas 
study did not observe the lower prevalence in IHPS with low birth weight observed in our 
study, but this may be because of differences in low birth weight categorizations used 
between studies (Wang et al., 2008).
With regard to parental characteristics, we observed increased IHPS prevalence among 
infants born to mothers <20 years of age at delivery, which supported some previous studies 
(Markel et al., 2015; Pedersen et al., 2008). Similarly, our observation of increased 
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prevalence among nulliparous mothers, supported some previous studies (Applegate & 
Druschel, 1995; Schechter et al., 1997) as did our observation of a decreased prevalence 
among infants born to mothers ≥35 years of age at delivery (Applegate & Druschel, 1995; 
Pedersen et al., 2008; Schechter et al., 1997). Additionally, the decreased prevalence 
observed for mothers with race/ethnicity other than non-Hispanic White was similar to those 
reported in three population-based studies (Applegate & Druschel, 1995; Lammer & 
Edmonds, 1987; Schechter et al., 1997). The association with maternal education at delivery 
in our study was consistent with three previous studies (Applegate & Druschel, 1995; 
Markel et al., 2015; To et al., 2005). The study by Wang et al. (2008) that used data which 
overlapped with our study tended to report similar associations between maternal 
characteristics (i.e., age, race/ethnicity, education, and parity) and IHPS.
Our observation of increased IHPS prevalence associated with younger paternal age was 
consistent with the findings of one previous study, although the results may not be directly 
comparable because of differences in paternal age categorization (Grewal et al., 2012). 
Associations with paternal age at delivery reported in a Texas study with data that 
overlapped those used in our study were similar for fathers ≥35 years of age, but not for 
those <20 years of age at delivery (Archer et al., 2007). Additionally, the decreased 
prevalence we observed among infants of fathers with a race/ethnicity other than non-
Hispanic White is the first examination of IHPS prevalence by paternal race/ethnicity.
Our study has several strengths. It represents one of the largest population-based studies of 
IHPS to date in the US, examining approximately 35% of US deliveries during the birth 
period included in the study. Our study also provides the most recent and longest temporal 
examination of IHPS prevalence estimates in the US. Along with these strengths, our study 
included a racially/ethnically diverse population, improving our ability to generalize findings 
to the US population. Other strengths include use of active case finding approaches at most 
of the participating surveillance programs; systematic approaches for record abstraction, 
including data on co-occurring birth defects; and population-based birth data from the 
corresponding jurisdictions for each surveillance program.
A limitation of our study was that data obtained from birth certificates may not always be 
reliable because of misclassification of information for gestational age (Barradas et al., 
2014; Dietz et al., 2014) and race/ethnicity (Mason, Nam, & Kim, 2014), and 
inconsistencies that may exist in how information is collected and reported on birth 
certificates by different states. Another limitation was the lack of IHPS data for the entire 
study period from three of the 11 participating surveillance programs. Also, we lacked data 
on selected infant and parental characteristics from some surveillance programs, as well as 
data on maternal behavioral and medication exposures that may contribute to IHPS, 
including maternal cigarette smoking during pregnancy (Krogh et al., 2012; Leite, Albieri, 
Kjaer, & Jensen, 2014; Markel et al., 2015; Sorensen, Norgard, Pedersen, Larsen, & 
Johnsen, 2002; Svenningsson et al., 2014) and maternal use of medications during 
pregnancy, such as any macrolide (Ludvigsson, Lundholm, Ortqvist, & Almqvist, 2016; 
Lund et al., 2014), erythromycin (Cooper et al., 2002; Louik, Werler, & Mitchell, 2002), 
azithromycin (Eberly, Eide, Thompson, & Nylund, 2015), decongestants (Yau, Mitchell, 
Lin, Werler, & Hernandez-Diaz, 2013), and bendectin (Eskenazi & Bracken, 1982). 
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Nonetheless, more than 99% of data were available for each selected infant or parental 
characteristic, except maternal race/ethnicity, parity, and paternal race/ethnicity, for which 
only 80%, 75%, and 67% of data, respectively, were available.
Using multistate population-based data covering one of the largest sample sizes and longest 
temporal period examined for IHPS in the US, our findings suggest that the prevalence of 
this birth defect appears to have decreased in the US during 2007–2010. Our descriptive 
analyses supported several previously reported findings, contributing to an increased 
understanding of selected infant and parental antecedents of IHPS. The suggestion of a 
decrease in IHPS prevalence warrants its continued monitoring to see if this pattern 
continues and to examine additional risk factors for IHPS to help explain the changing 
prevalence of this defect.
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FIGURE 1. 
Inclusion of state-specific population-based birth defect surveillance program data for 
prevalence and descriptive analysis of infantile hypertrophic pyloric stenosis, 1999–
2010.†Surveillance programs excluded because of no available data for one or more birth 
years. ‡Surveillance programs excluded because of no available data for one or more infant 
or parental characteristics. §Surveillance programs excluded because of no available data for 
one or more infant or maternal characteristics included in the adjusted model
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FIGURE 2. 
Prevalence (per 10,000 live births) of infantile hypertrophic pyloric stenosis across eight 
United States population-based birth defect surveillance programs, 1999–2010.Vertical bars 
represent 95% confidence intervals around the prevalence estimates
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FIGURE 3. 
Adjusted prevalence ratios and 95% confidence intervals for associations between selected 
infant and parental characteristics and (a) all male cases, (b) isolated male cases, (c) all 
female cases, and (d) isolated female cases of infantile hypertrophic pyloric stenosis in seven 
United States population-based birth defect surveillance programs†, 1999–2005.
aPRs = adjusted prevalence ratios; H = Hispanic; NHB = Non-Hispanic Black; NHW = 
Non-Hispanic White; R/E = race/ethnicity. †includes data from Arkansas, Arizona, Georgia, 
Iowa, North Carolina, Oklahoma, and Texas
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TABLE 3
Adjusted prevalence ratios and 95% confidence intervals for associations between selected infant and parental 
characteristics and infantile hypertrophic pyloric stenosis in seven United States population-based birth defect 
surveillance programsa, 1999–2005
Characteristics All cases aPR (95% CI) Isolated cases aPR (95% CI)
Infant
Sex
 Male 4.37 (4.11, 4.64) 4.39 (4.11, 4.71)
 Female Referent Referent
Birth weight (grams)
 <2,500 0.47 (0.43, 0.51) 0.40 (0.35, 0.44)
 ≥2,500 Referent Referent
Gestational age (weeks)
 <37 1.57 (1.45, 1.69) 1.49 (1.36, 1.63)
 ≥37 Referent Referent
Plurality
 1 Referent Referent
 2 or more 1.75 (1.54, 1.98) 1.80 (1.56, 2.06)
Maternal
Age at delivery (years)
 <20 1.06 (0.98, 1.16) 1.08 (0.99, 1.19)
 20–34 Referent Referent
 ≥35 0.89 (0.81, 0.97) 0.88 (0.80, 0.98)
Race/ethnicity
 Non-Hispanic White Referent Referent
 Non-Hispanic Black 0.44 (0.36, 0.53) 0.45 (0.37, 0.55)
 Hispanic 0.81 (0.74, 0.88) 0.78 (0.70, 0.86)
 Otherb 0.66 (0.55, 0.78) 0.67 (0.55, 0.81)
Education (years)
 <12 0.99 (0.93, 1.05) 1.00 (0.93, 1.08)
 12 Referent Referent
 >12 0.70 (0.66, 0.74) 0.69 (0.64, 0.73)
Parityc
 0 1.29 (1.23, 1.36) 1.26 (1.19, 1.34)
 1 or more Referent Referent
Paternal
Age at delivery (years)
 < 20 1.07 (0.96, 1.20) 1.10 (0.97, 1.24)
 20–34 Referent Referent
Birth Defects Res. Author manuscript; available in PMC 2020 March 23.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Kapoor et al. Page 20
Characteristics All cases aPR (95% CI) Isolated cases aPR (95% CI)
 ≥ 35 0.86 (0.80, 0.93) 0.85 (0.79, 0.92)
Race/ethnicity
 Non-Hispanic White Referent Referent
 Non-Hispanic Black 0.75 (0.64, 0.88) 0.74 (0.61, 0.88)
 Hispanic 0.97 (0.89, 1.06) 0.94 (0.85, 1.04)
 Otherb 0.78 (0.65, 0.92) 0.83 (0.68, 1.00)
Abbreviations. aPR = adjusted prevalence ratio; CI = confidence intervals.
a
Includes data from Arkansas, Arizona, Georgia, Iowa, North Carolina, Oklahoma, and Texas.
b
Includes Asians/Pacific islanders, Native Americans, and other race/ethnic groups.
c
Includes previous live and previous nonlive births.
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